高庆蕾;孔北华;尹如铁;王珂;吕卫国;刘继红;吴鸣;郑虹;周琦;谢幸;程文俊;马丁;

• 1:华中科技大学同济医学院附属同济医院
• 2:山东大学齐鲁医院
• 3:四川大学华西第二医院
• 4:天津市肿瘤医院

摘要(Abstract)：

<正>卵巢癌是最常见的妇科生殖系统肿瘤之一。全球每年新发卵巢癌约23.9万例,死亡15.2万例,占女性恶性肿瘤发生率第7位[1]。根据2015年郝捷院士发表的中国癌症统计数据,我国年新发卵巢癌5.2万余例,死亡2.25万例;发病率年增加6.3%,死

关键词(KeyWords)： PARP抑制剂;卵巢癌

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 高庆蕾;孔北华;尹如铁;王珂;吕卫国;刘继红;吴鸣;郑虹;周琦;谢幸;程文俊;马丁;

DOI: 10.13283/j.cnki.xdfckjz.2018.10.001

参考文献(References)：

• [1]Reid BM,Permuth JB,Sellers TA.Epidemiology of ovarian cancer:a review[J].Cancer Biol Med,2017,14(1):9-32
• [2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132
• [3]Howlader N,Noone A,Krapcho M,et al.SEER Cancer Statistics Review,1975-2008,National Cancer Institute.Bethesa,MD,Available from:http://seer.cancer.gov/csr/1975_2008/,based on November 2010 SEER data submission,posted to the SEER web site,2011
• [4]易晓芳,丰有吉.复发性卵巢癌的化疗进展[J].肿瘤学杂志,2006,12(2):99-102
• [5]李克敏,尹如铁.复发性卵巢癌的化学治疗[J].实用妇产科杂志,2017,33(11):815-818
• [6]Tinker AV,Gelmon K.The role of PARP inhibitors in the treatment of ovarian carcinomas[J].Curr Pharm Des,2012,18(25):3770-3774
• [7]Ledermann JA,Drew Y,Kristeleit RS.Homologous recombination deficiency and ovarian cancer[J].Eur J Cancer,2016,60(1):49-58
• [8]Lux MP,Fasching PA,Beckmann MW.Hereditary breast and ovarian cancer:review and future perspectives[J].JMol Med(Berl),2006,84(1):16-28
• [9]Farmer H,McCabe N,Lord CJ,et al.Targeting the DNArepair defect in BRCA mutant cells as a therapeutic strategy[J].Nature,2005,434(7035):917-921
• [10]Walsh CS.Two decades beyond BRCA1/2:Homologous recombination,hereditary cancer risk and a target for ovarian cancer therapy[J].Gynecol Oncol,2015,137(2):343-350
• [11]FDA approves olaparib tablets for maintenance treatment in ovarian cancer.Available from:https://www.fda.gov/Drugs/Information On Drugs/Approved Drugs/ucm572143.htm
• [12]FDA approves first treatment for breast cancer with a certain inherited genetic mutation.Available from:https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm592347.htm
• [13]FDA approves rucaparib for maintenance treatment of recurrent ovarian,fallopian tube,or primary peritoneal cancer.Available from:https://www.fda.gov/Drugs/Information On Drugs/Approved Drugs/ucm603997.htm
• [14]FDA approves maintenance treatment for recurrent epithelial ovarian,fallopian tube or primary peritoneal cancers.Available from:https://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm548948.htm
• [15]Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].N Engl J Med,2012,366(15):1382-1392
• [16]Friedlander M,Trimble E,Tinker A,et al.Clinical trials in recurrent ovarian cancer[J].Int J Gynecol Cancer,2011,21(4):771-775
• [17]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RE-CIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247
• [18]Charlie G,Michael F,Ursula M,et al.Clinically significant long-term maintenance treatment with Olaparib in patients with platinum-sensitive relapsed serous ovarian cancer.2017 ASCO,abstract 5533
• [19]Pujade-Lauraine E,Ledermann JA,Selle F,et al.Olaparib tablets as maintenance therapy in patients with platinumsensitive,relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21):a double-blind,randomised,placebo-controlled,phase 3 trial[J].Lancet Oncol,2017,18(9):1274-1284
• [20]Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib Maintenance Therapy in Platinum-Sensitive,Recurrent Ovarian Cancer[J].N Engl J Med,2016,375(22):2154-2164
• [21]Coleman RL,Oza AM,Lorusso D,et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10106):1949-1961
• [22]Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447Orig1s000MultidisciplineR.pdf
• [23]Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncol,2014,15(8):852-861
• [24]Pujade-Lauraine,Ledermann JA,Penson RT,et al.Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer:Results from the phase III SOLO2 study.Available from:https://www.sgo.org/education/annual-meeting-on-womens-cancer/annual-meeting-late-breaking-abstracts/2017
• [25]Kaufman B,Shapira-Frommer R,Schmutzler RK,et al.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J].J Clin Oncol,2015,33(3):244-250
• [26]Domchek SM,Aghajanian C,Shapira-Frommer R,et al.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J].Gynecol Oncol,2016,140(2):199-203
• [27]Coleman RL,Sill MW,Bell-McGuinn K,et al.A phase II evaluation of the potent,highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian,fallopian tube,or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation-An NRG Oncology/Gynecologic Oncology Group study[J].Gynecol Oncol,2015,137(3):386-391
• [28]Oza AM,Cibula D,Benzaquen AO,et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer:a randomised phase 2 trial[J].Lancet Oncol,2015,16(1):87-97
• [29]Liu JF,Barry WT,Birrer M,et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:a randomised phase 2 study[J].Lancet Oncol,2014,15(11):1207-1214
• [30]Ivy SP,Liu JF,Lee JM,et al.Cediranib,a pan-VEGFR inhibitor,and olaparib,a PARP inhibitor,in combination therapy for high grade serous ovarian cancer[J].Expert Opin Invest Drugs,2016,25(5):597-611
• [31]Drew Y,de Jonge M,Hong SH,et al.An open-label,phase IIbasket study of olaparib and durvalumab(MEDIOLA):Results in germline BRCA-mutated(g BRCAm)platinum-sensitive relapsed(PSR)ovarian cancer(OC).2018
• [32]Konstantinopoulos P,Munster P,Forero-Torres A,et al.TOPACIO:preliminary activity and safety in patients(pts)with platinum-resistant ovarian cancer in a phase 1/2 study of niraparib in combination with pembrolizumab.Presented at:SGO Annual Meeting;March 24-27,2018;New Orleans,LA.Late-breaking abstract